SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-045091
Filing Date
2023-06-01
Accepted
2023-06-01 17:00:10
Documents
15
Period of Report
2023-05-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea179534-8k_allarity.htm   iXBRL 8-K 39029
2 FIRST CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF DESIGN ea179534ex3-1_allarity.htm EX-3.1 26249
3 FIRST AMENDMENT TO THE MODIFICATION AND EXCHANGE AGREEMENT ea179534ex10-1_allarity.htm EX-10.1 11826
4 FOURTH AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT ea179534ex10-2_allarity.htm EX-10.2 16900
  Complete submission text file 0001213900-23-045091.txt   287599

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE allr-20230526.xsd EX-101.SCH 2959
6 XBRL LABEL FILE allr-20230526_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE allr-20230526_pre.xml EX-101.PRE 22359
9 EXTRACTED XBRL INSTANCE DOCUMENT ea179534-8k_allarity_htm.xml XML 3827
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 23985488
SIC: 2834 Pharmaceutical Preparations